報價延遲最少15分鐘:2025/11/16 02:39 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.85 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-18.93/-0.74
|
|
企業價值
3.66M
|
| 資產負債 |
|
每股賬面淨值
-0.70
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/16 02:39 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors& neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease. |
